Healthcare Global Enterprises Limited — PPTs, 16-02-2025: Investor Presentation

Financial Highlights: HealthCare Global Enterprises Limited reported a revenue increase to ₹5,586 million for Q3FY25, up 19% year-on-year, with HCG centers contributing ₹5,450 million (+20%), while the Milann centers saw a decrease in revenue to ₹136 million (-17%). Adjusted EBITDA margin was 16.5%, slightly lower than the previous year. Profit after tax (post-Ind AS) rose to ₹111 million, a 22% increase. For the first nine months of FY25, revenue reached ₹16,377 million (+16%), driven primarily by HCG centers.

Strategic Initiatives and Growth Drivers: The company is focusing on expanding its footprint and enhancing operational efficiency. Significant investments in technology and training are aimed at establishing HCG as a leader in cancer care across India.

Business Developments: Noteworthy growth was observed in multiple regions, including Kolkata, which achieved a 40% increase in revenue y-o-y. HCG has successfully positioned itself as a premier oncology care provider, bolstered by strategic acquisitions and expansion in non-metro areas.

Market Position and Competitive Advantage: HCG maintains a strong market presence with over 21 centers, underscoring its extensive reach in the oncology sector. The unique specialization in cancer care positions HCG favorably against general hospitals, enhancing the company's competitive standing.

Investor Implications: With sustained revenue growth and strategic focus on operational improvements, HCG presents a positive outlook for investors, showcasing potential for further gains as it leverages emerging market opportunities and enhances patient care offerings.